BioXcel Therapeutics, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
BioXcel Therapeutics appointed Susan E. Atkins as an independent director effective August 12, 2026. Atkins receives $25,000/month base compensation, $5,000/day for duties beyond normal board service, and 17,000 stock options under the non-employee director compensation program. A contemporaneous indemnification agreement provides broad D&O protection including advancement of legal expenses and post-service indemnification.
Why this rating
Routine director appointment and standard compensation package. Relative to $11M market cap, ~$300k annualized base (2.7% of company value) plus options represent normal board governance costs, not material business change.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.